INCY Mar 2025 85.000 put
| Previous close | 21.57 |
| Open | 21.57 |
| Bid | 17.40 |
| Ask | 21.40 |
| Strike | 85.00 |
| Expiry date | 2025-03-21 |
| Day's range | 21.57 - 21.57 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksIncyte Gains 12.7% Year to Date: How Should You Play the Stock?
Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.
Business WireMultiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
WILMINGTON, Del., September 25, 2024--Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the EADV 2024 Congress
PR NewswireIncyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that results from the pivotal Phase 2 AGAVE-201 trial of Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients with recurrent/refractory active chronic graft-versus-host disease (GVHD) who had received at least two prior lines of systemic therapy were published in The New England Journal of Medicine.1 The publication, entitled "Axatilimab in Recurrent or Refractory Chronic Graft-Versus-H
